



Severe to Very Severe Hypertriglyceridemia Management

INTRODUCTION

Patients admitted with severe to very severe hypertriglyceridemia (HTG) are at risk of developing acute pancreatitis (Esparza et al., 2019; Frankova et al., 2019; Garg & Rustagi, 2018; Gelrud & Whitcomb, 2021; He et al., 2020; Sezgin et al., 2019; Thuzar et al., 2014; Uyar et al., 2017; Yildirim et al., 2019).

Third most common cause of pancreatitis is HTG, accounting for up to 14% of cases in reviewed literature (Frankova et al., 2019; Gelrud & Whitcomb, 2021; Thuzar et al., 2014; Yildirim et al., 2019)

Terminology:

- Severe HTG- triglyceride level of 1000-1999 mg/dL
- Very Severe HTG- triglyceride level ≥ 2000 mg/dL (Gelrud & Whitcomb, 2021)

Pathogenesis of HTG induced acute pancreatitis (IAP):

- Happens when free fatty acids produced by the breakdown of triglycerides cause lipotoxicity and an inflammatory response (Gelrud & Whitcomb, 2021)

Diagnosis:

- 2 of 3 findings must be present- abdominal pain, serum pancreatic enzymes at least 3x normal level, & imaging revealing pancreatitis (Garg & Rustagi, 2018; Gelrud & Whitcomb, 2021; Sezgin et al., 2019)

Background

- At an Intensive Care Unit (ICU) in Texas, United States, nursing anecdotally observed an increase in patients diagnosed with HTG requiring insulin therapy
- No current specific protocol & policy for managing patients with severe to very severe HTG was available per hospital
- Investigators sought to answer the question, "In adults (>18 of age) with severe to very severe HTG-IAP, what evidence-based treatment in addition to continuous insulin therapy should be employed during inpatient hospitalization?"

REFERENCES

Esparza, M. L., Li, X., Adams-Huet, B., Vasandani, C., Vora, A., Das, S. R., Garg, A., & Ahmad, Z. (2019). Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management. *Journal of the Endocrine Society*, 3(8), 1595-1607.

Frankova, D., Olson, K. M., Whyms, B. J., Guevara Hernandez, M. A., & Franko, J. (2018). The effect of intravenous insulin, apheresis and oral lipid-lowering agents on non-fasting hypertriglyceridemia and associated pancreatitis. *Postgraduate Medicine*, 130(5), 494-500. <https://doi.org/10.1080/00254812.2018.1470439>

Garg, R., & Rustagi, T. (2018). Management of Hypertriglyceridemia Induced Acute Pancreatitis. *BioMed Research International*, 2018, 4721357. <https://doi.org/10.1155/2018/4721357>

Gelrud, A., & Whitcomb, D. C. (2021). Hypertriglyceridemia-induced acute pancreatitis. *UpToDate*. https://www.uptodate.com/contents/hypertriglyceridemia-induced-acute-pancreatitis/printsearch/hypertriglyceridemia%20induced%20pancreatitis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

He, W., Cai, W., Camilleri, G., Yang, X., Zhu, P., Mukherjee, R., Huang, W., Sutton, R. (2020, November 1). *Insulin versus blood purification in the early management of hypertriglyceridemia-associated acute pancreatitis: systematic review and meta-analysis*. www.clinicalkey.com

Magradze, T., & Shelestova, E. (2018). Clinical Case Report on Acute Pancreatitis with Concomitant T2dm and Hypertriglyceridemia. *Georgian Medical News*, 277, 39-44.

Roney, J. K., Whittle, B. E., Maples, J. C., Futrell, L. S., Stunkard, K. A., Long, J. D. Modified early warning scoring (MEWS): Evaluating the evidence for tool inclusion of sepsis screening criteria and impact on mortality and failure to rescue. *Journal of Clinical Nursing* (John Wiley & Sons, Inc), 2015;24(23-24):3343-3354. doi:10.1111/jocn.12952.

Sezgin, O., Ozdogan, O., Yaras, S., Uzbilic, E., & Altintas, E. (2019). Evaluation of hypertriglyceridemia-induced acute pancreatitis: A single tertiary care unit experience from Turkey. *The Official Journal of Turkish Society of Gastroenterology*, 30(3), 271-277. <https://doi.org/10.5152/tjg.2018.18292>

Thuzar, M., Shenoy, V. V., Malabu, U. H., Schralke, R., & Sangla, K. S. (2014). Extreme hypertriglyceridemia managed with insulin. *Journal of Clinical Lipidology*, 8(6), 630-634. <https://doi.org/10.1016/j.jacl.2014.09.004>


Uyar, S., Harmandar, F., Kok, M., Tas, Z., Dolu, S., Tokuc, A., Koker, G., Gorar, S., & Cekin, A. H. (2017). Management of hypertriglyceridemia induced acute pancreatitis and therapeutic plasmapheresis: Report of nine cases and review of literature. *Acta Gastro-Enterologica Belgica*, 80(1), 71-74.

YILDIRMIM SİMSİR, I., SOYALTI, U. E., SAHER YONREKLI, B., ERDOĞAN, M., ÇETINKALP, Ş., SAYGILI, F., DÖNMEZ, A., & ÖZGEN, A. G. (2019). Therapeutic plasma exchange in hypertriglyceridemic patients. *Turkish Journal of Medical Sciences*, 49(3), 872-878.

Methods

- Literature review search completed April 8, 2021
- Search terms: "hospitalized" AND "adult" AND "hypertriglyceridemia" AND "management" AND "insulin" (3,130 results)
- Current (<5 years) literature search through 2021 limited to English yielded 759 peer-reviewed publications.
- Once screened for relevancy by title (n=17), abstracts (n=8), and full text (n=7).
- Three additional articles were identified through snowballing information in UpToDate and ClinicalKey, for a final sample of ten manuscripts.
- Synthesis of findings was facilitated using a research table for documentation of key findings and discussion.
- Level of Evidence: Level 1 (n=1), Level 2 (n=1), Level 4 (n=2), Level 6 (n=5), Level 7 (n=1)

Suggested hypertriglyceridemia algorithm



MEWS Tool utilized at Covenant Health

Modified Early Warning Score (MEWS) MEWS is designed to identify patient deterioration and ensure early intervention. Use clinical judgement too

MEWS	3	2	1	0	1	2	3
TEMP (F)	≥ 101.0	≥ 99.0	98.5-98.8	96.5-100.4	100.5-101.4	≥ 101.5	
Systolic BP	≤ 70	71-90	91-100	101-130	100-100	≥ 200	
Respiratory rate	≤ 9	10-20	21-29	30-39	40-49	≥ 50	
Heart rate	≤ 50	51-90	91-130	131-170	171-210	≥ 210	
UO ₁ (ml/hr)	≤ 7	8-11	12-20	21-23	24-29	≥ 30	
LOC	Unresponsive	Responds to pain	Responds to voice	Alert	Agitation or Irritability	Confusion	Delirious
WBC	Lactic Acid > 4 = RT Call	< 4,000	4,000-12,000	< 12,000	> 12,000		
Urine Output	< 30 ml/hr or Patient on dialysis	> 30 ml/hr or Patient on dialysis					

Legend: G = Green, Y = Yellow, O = Orange, R = Red

Lipid in Blood Sample



RESULTS

Multiple causes include pregnancy, alcoholism, obesity, specific drugs, especially diabetes mellitus (Esparza et al., 2019; Magradze & Shelestova, 2018; Gelrud & Whitcomb, 2021; Thuzar et al., 2014)

No significant difference in patients who received intravenous insulin therapy (IT) versus blood purification therapy (BPT) (Frankova et al., 2019; Garg & Rustagi, 2018; Gelrud & Whitcomb, 2021; He et al., 2020; Sezgin et al., 2019; Yildirim et al., 2019)

Treatment goal of triglyceride level <500 mg/dL (Esparza et al., 2019; Frankova et al., 2019; Garg & Rustagi, 2018; Gelrud & Whitcomb, 2021; He et al., 2020; Sezgin et al., 2019; Thuzar et al., 2014; Uyar et al., 2017; Yildirim et al., 2019)

Once treatment goal met, recommendation to start fibrates, niacin, omega 3 fatty acid, and statins (Garg & Rustagi, 2018; Gelrud & Whitcomb, 2021; Magradze & Shelestova, 2018; Sezgin et al., 2019)

Recommendation to initiate BPT with organ dysfunction (Uyar et al., 2017; Gelrud & Whitcomb, 2021)

IT with fasting seen in one study to significantly reduce triglyceride level compared to use of IT without fasting (He et al., 2020; Thuzar et al., 2014)

IMPLICATIONS FOR PRACTICE

- Strong foundational comprehension of HTG-IAP care interventions enables care providers to advocate for evidence-based treatment interventions.
- Having these interventions initiated rapidly through the development of protocols and order sets ensures reliable treatment for the best outcomes.
- Additional research to evaluate IT, BPT, and lipid-lowering medications' efficacy for HTG-IAP evidence-based treatment management strategies should be studied further.

CONCLUSION

- Answering the question of HTG-IAP treatment with IT and/or BPT was supported with limited evidence in peer-reviewed literature
- Nurses applying evidence-based management options for HTG-IAP in hospitalized patients may ensure reduced adverse outcomes
- Evidence-based treatment strategies must be readily accessible at the point of care delivery in easy-to-apply formats such as protocols and order sets